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Context-dependent signalingla et al. [T. Hermosilla, D. Munoz, R. Herrera-Molina, A. Valdivia, N. Munoz, S.U.
Nham, P. Schneider, K. Burridge, A.F. Quest, L. Leyton, Direct Thy-1/alphaVbeta3 integrin interaction mediates
neuron to astrocyte communication, Biochim Biophys Acta 1783 (2008) 1111–1120] demonstrates that Thy-1
on neurons binds to αvβ3 integrin on astrocytes via a conserved RLD motif, triggering the formation of focal
adhesions and stress ﬁbers via tyrosine phosphorylation and RhoA activation. This study adds to growing
evidence regarding the signaling mechanisms and biological roles of Thy-1, an important regulator of
context-dependent signaling. As knowledge of Thy-1 approaches its ﬁftieth year, it is critical to begin to
synthesize insights from different ﬁelds to determine how this heretofore enigmatic molecule modulates cell
behavior in both cis and trans.
© 2008 Elsevier B.V. All rights reserved.Thy-1 (CD90) is a developmentally regulated, evolutionarily
conserved cell surface glycoprotein, the biological role of which
remains somewhat enigmatic despite hundreds of intriguing
publications over the past forty-ﬁve years. Part of the reason that
Thy-1 is still a bit mysterious is that, though it is by no means
ubiquitous, it is expressed in a heterogeneous range of cell types,
including thymocytes, lymphocytes, ﬁbroblasts, neuronal cells,
hematopoietic and mesenchymal stem cells, ovarian follicular cells,
and some cancer cells. It therefore has implications in a number of
ﬁelds, including neurobiology, immunology, oncology, stem cell
biology and wound healing. In each of these areas, investigators
have tended to home in on one aspect of the function of Thy-1, in a
particular cell type. Thus the ﬁeld suffers a bit from the well-known
“blind men and the elephant” metaphor, in which no one has the
big picture. Furthermore, the Thy-1 null mouse is viable and has
subtle and diverse phenotypic features. Its characterization has been
somewhat piecemeal, in keeping with the above observations. In the
minds of many, Thy-1 has been relegated to the role of a mere
marker; useful for identifying some ﬁbroblasts, stem cells and
neurons (in a colorful, even whimsical way in the case of the Thy-1-
Brainbow transgenic mouse [2]), but failing to enter the pantheon of
“vitally important” molecules.
Part of Thy-1's scientiﬁc facelessness results from its lack of a
deﬁned ligand; its failure to associate with molecules of interest. The
article by Hermosilla et al [1] addresses this deﬁciency in part by
clearly demonstrating, using a systematic, combinatorial approach,1 205 9962333.
.H. Barker), jhagood@uab.edu
ll rights reserved.heterotypic binding of neuronal Thy-1 to αvβ3 integrin on astrocytes,
inducing focal adhesion formation and cytoskeletal alterations via
RhoA GTPase activation. The ﬁndings have implications for neurode-
velopment and neural repair, and begin to paint a clearer picture of
Thy-1's role with regard to signaling. The immunologic and non-
immunologic functions of Thy-1 andwhat is known about its signaling
mechanisms have been reviewed previously [3–5]; this mini-review
will focus on recent ﬁndings in two broad paradigms in Thy-1
signaling, attempt to put these ﬁndings in a broader biological context,
and suggest areas for future exploration.
Thy-1 can affect signaling heterotypically (in trans) by “effector
cell” Thy-1 binding to a Thy-1 ligand on a “target cell” (Fig. 1A). This is
the paradigm illustrated in the Hermosilla paper. Reported ligands for
Thy-1 trans- signaling are β2 and β3 integrins. Speciﬁcally, human
dermal microvascular endothelial cell (HDMEC) Thy-1 binds to αXβ2
(p 150,95, CD11c/CD18) orαMβ2 (Mac-1, CD11b/CD18) on leukocytes,
promoting their adhesion and transendothelial migration [6–8].
Melanoma cells appear to bind instead via αvβ3 integrin to Thy-1 on
activated endothelium [9,10], which may facilitate melanoma metas-
tasis. Thy-1 has been known to inhibit neurite outgrowth on
astrocytes for many years [11]. Leyton et al initially described how
this interaction produces focal adhesion changes in astrocytes as well,
and deﬁned a role for β3 integrin in this heterotypic signaling [12].
This group has continued to dissect this interaction, and the current
study demonstrates deﬁnitively the role of the αvβ3 heterodimer, and
more clearly deﬁnes the signaling in astrocytes downstream of αvβ3
[1]. A number of novel ﬁndings are reported. The α chain of the αvβ3
heterodimer identiﬁed by immunoprecipitation from DI TNC1 rat
astrocytes was of smaller-than-expected molecular size, suggesting
alternative splicing or post-translational modiﬁcation. However, “full-
length” αvβ3 binds to Thy-1 in vitro by surface plasmon resonance.
Fig. 1. Thy-1 (CD90) Signaling. (A) Trans Signaling: Simpliﬁed scheme of Thy-1 heterotypic signaling. Colored text indicates effector and responder cells for the downstream effects
noted. (B) Cis Signaling: Colored dots in the light blue box correspond to colored text for the cell types in which the indicated responses have been described. For further details
regarding the signaling pathways involved, the reader is referred to the text and to several relevant reviews [3–5].
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but may be upregulated in response to injury. Hermosilla et al also
demonstrate a requirement for the RLD tripeptide in Thy-1 in binding
to αvβ3 integrin. This sequence is found within a highly conserved
region (70% human–rat–mouse homology in the 10 amino acids
ﬂanking RLD in both directions) of Thy-1, and is similar to the αMβ2-
binding region in ﬁbrinogen [13]. It is suggested that other portions of
the Thy-1 molecule, such as the GPI anchor, are not required for trans-
signaling through αvβ3, as Thy-1-Fc fusion protein on microspheres
appears equally capable of mediating focal adhesion formation on
astrocytes. This ﬁnding also would seem to negate the need for Thy-1
in “effector” cells (e.g., neurons) to be present within lipid rafts. The
signaling pathway stimulated by Thy-1 via αvβ3 involves focal
adhesion kinase (FAK) and RhoA GTPase. Interestingly, these are
pathways which we have observed in association with homotypic (in
cis) Thy-1 signaling in pulmonary ﬁbroblasts [14–16], as discussed
further below. The neuron-astrocyte interaction also involves Thy-1
cis signaling in neurons (neurite outgrowth inhibition); however,
the Thy-1-interacting molecules within neurons, and the downstream
signaling pathways activated, have yet to be identiﬁed. Others have
shown that neurite outgrowth inhibition requires lipid raft integrity,
as well as the Thy-1-speciﬁc GPI anchor [11].
Thy-1 also signals homotypically (in cis), through interaction
with TCR, via Thy-1 crosslinking, or through unknown mechanisms
(Fig. 1B). The latter two must by necessity involve interaction with
other molecules, as Thy-1 lacks a transmembrane or cytoplasmic
portion. We and others have previously established Thy-1's
interaction with members of the Src family kinases (SFKs; e.g.,
via association of the GPI anchor with palmitoylated residues on
Src family members such as fyn and lyn [17]). Immunoprecipitation
of Thy-1 from cell lysates co-precipitates SFKs [18]. Evidence for cis
signaling of Thy-1 can be derived from pulmonary ﬁbroblast
subpopulations sorted based on their surface expression of Thy-1.
Thy-1-expressing ﬁbroblasts display altered phenotypic responses
to growth factors, cytokines, and adhesion proteins. Theseresponses have been partially explained by regulation of down-
stream signaling proteins such as phosphoinositide-3 kinase (PI3K)
and SFKs. In response to the matricellular protein thrombospondin,
Thy-1-expressing ﬁbroblasts will disassemble focal adhesions in a
PI3K- and SFK-mediated manner [15]. Lack of cell surface Thy-1
abrogates this effect, which can be rescued by exogenous Thy-1
expression following transfection. Furthermore, the baseline activity
of the SFK-p190 Rho GTPase-activating protein (GAP) pathway is
dependent on Thy-1 expression. Exogenous expression of Thy-1 on
Thy-1-nonexpressing ﬁbroblasts results in inhibition of SFK activity
and subsequent activation of RhoA, leading to focal adhesion
assembly and stress ﬁber formation [14]. Equally important to Thy-
1 cis signaling is the integrity of lipid raft micro- and nanodomains.
Through its GPI linkage, Thy-1 has been shown to have equal
mobility in cholesterol-rich lipid rafts as in the bulk plasma
membrane, which facilitates its trafﬁcking into and out of lipid raft
domains, whereas transmembrane proteins and other moieties are
more spatially restricted [19]. This inherent mobility may play a
role in Thy-1's capacity to facilitate cis signaling as demonstrated
by the fact that Thy-1 localization to lipid rafts and lipid raft
integrity appear critical to Thy-1's effect on signaling. Either
replacement of the GPI linkage with a membrane-spanning domain
or disruption of lipid rafts with methyl-beta-cyclodextrin (MβCD)
disrupts Thy-1-mediated signaling [11,16]. Recently, strong evidence
has been presented that implies a role for Thy-1 in the association
of lipid rafts with the actin cortex immediately adjacent to the
plasma membrane. Clustering of Thy-1 with antibody-coated gold
nanoparticles followed by particle tracking demonstrates that Thy-1
sorts into, resides within, and migrates out of distinct lipid
nanodomains. The residence time within the nanodomains appears
controlled by associations with the cell cytoskeleton [20]. Taken
together, these data are suggestive of a role of Thy-1 in the
trafﬁcking and partitioning of signaling molecules into and out of
specialized lipid rafts for higher order signaling networks asso-
ciated with the cytoskeleton. In this way Thy-1 may act alternately
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signaling molecules such as SFKs.
In order to truly understand the effects of Thy-1 on signaling
networks in both cis and trans, signiﬁcant further studies are required.
As yet, no comprehensive search for cis binding partners has been
reported. While clear demonstration of the trans interaction with
αvβ3 via RLD is a signiﬁcant breakthrough, it is clear that Thy-1
interacts with other cell surface molecules in a planar fashion. Does
Thy-1 also associate with integrin in cis? The role of Thy-1 in
regulating the Rho GTPases, focal adhesion assembly/disassembly,
and stress ﬁber formation are suggestive that cis interactions with
integrin occur, but studies are required to demonstrate this, as well as
to systematically determine other Thy-1 binding partners. Further-
more, the mechanisms regulating Thy-1 localization and trafﬁcking to
specialized and distinct lipid nanodomains present a signiﬁcant
challenge that is likely to provide further insights into Thy-1's role
in coordinating signaling networks. Substitution of peptide sequences
that direct GPI linkages in the endoplasmic reticulumwould allow the
interrogation of the effects of Thy-1 localization on signaling networks
and downstream cell biology. The recent publications describing Thy-
1's relative mobility and residence time in speciﬁc plasma membrane
domains and the unexpected ability of Thy-1 to connect lipid rafts to
underlying cytoskeletal networks uncovers a completely unexplored
topic with direct relevance to Thy-1's documented activity in
regulating cell cytoskeletal organization and changes.
The evidence for Thy-1 binding to integrin and regulation of
cytoskeletal signaling and organization make it ideally located to
affect critical cellular events, such as cell motility, mitotic lift-off,
and potentially epithelial to mesenchymal transition. The fact that
the molecule is shed from the surface [21,22] and could thus
directly interact as a soluble factor, acting potentially as an
inhibitor of cell adhesion, further complicates our understanding
of the role of this protein in normal physiology and pathological
progression. What remains clear is that the expression of Thy-1 has
signiﬁcant consequences for the phenotype of many cells. Despite
our lack of understanding of the nuances of Thy-1 mechanisms, it
is clear we can no longer be naïve in the assumption that Thy-1 is
simply a marker. It appears instead to be an integral protein in
deﬁning cell behavior during normal homeostasis as well as during
tissue repair.
Other important aspects of Thy-1 biology not reviewed here
include evolution of Thy-1, regulation of Thy-1 expression, post-
translational modiﬁcation of Thy-1, including glycosylation and
shedding, and potential interaction with lectins. Even by focusing
merely on Thy-1 signaling in cis and trans, however, it is clear that
Thy-1 exerts signiﬁcant effects on signaling modulating cell–cell
and cell–matrix interaction, via interesting and possibly unique
mechanisms involving changes in both target and effector cells.
Thy-1 thus emerges as an important modulator of context-
dependent signaling, which alters interaction of cells with each
other and with their immediate environment. Some of the most
challenging problems in biomedicine today are disorders of
neurodevelopment and neural repair after injury, regulation of
stem cell pluripotency and differentiation, cancer metastasis, and
progressive ﬁbrotic diseases. Given the fact that Thy-1 has a role in
all of these processes, the era of seeing Thy-1 as a marker, or of
compartmentalized, nearsighted analysis of its function is over. As
Thy-1 enters its second half-century, it is time to start looking at
the big picture.References
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